Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 23, Issue 5, Pages E1193-E1196Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000035
Keywords
hemophagocytic lymphohistiocytosis; visceral leishmaniasis; Leishmania; tocilizumab; interleukin 6
Categories
Ask authors/readers for more resources
Leishmaniasis is important as a cause of hemophagocytic lymphohistiocytosis (HLH) and must be considered and excluded in patients with HLH because it can cause severe or even fatal complications. When HLH is present, there is a deficient downregulation of the immune response, leading to an uncontrolled inflammation. We report a case of visceral leishmaniasis-HLH where the therapy with tocilizumab, targeting interleukin 6, help to regulate the immune response for the infection of Leishmania.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available